Evidence map›Paper›PMID 41495388›Full record

ArticleNPJ digital medicine2026

Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC.

Yu Dong, Wenjiao Xia, Zitong Yang, Liangliang Ren, Hongru Wang, Yiyang Zhou, Qinchen Li, Zhi Chen, Zhinan Xia, Yichun Zheng and 15 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yu Dong *Department of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Wenjiao Xia *Department of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Zitong Yang *Department of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Liangliang Ren *Department of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Hongru Wang *Department of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Yiyang ZhouDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Qinchen LiDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Zhi ChenDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Zhinan XiaDepartment of Urology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Yichun ZhengDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Feifan WangDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ning HeDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Bing ChengDepartment of Geriatric Medicine, Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
Dongmei MaDepartment of Anesthesiology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Wei ShaoState Key Laboratory of Green Chemistry Synthesis Technology, College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, China.
Wei GuoDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Shuwen WangDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Ziqiao LiuDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Junxiao ShenDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Yiming QiDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Xuke GongDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Juan JinDepartment of Nephrology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. 20233004@zcmu.edu.cn.
Bo XieDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. zdyyxb@zju.edu.cn.
Guixin ZhuDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China. zhuguixin@zju.edu.cn.
Cheng ZhangDepartment of Urology, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China. zhangcheng13836182568@zju.edu.cn.

Funding

Hangzhou Medical and Health Technology Project B20241639Key Project of Natural Science Foundation of Zhejiang Province LZ22H160008National Natural Science Foundation of China 22075249National Natural Science Foundation of China 32370749National Natural Science Foundation of China 82372731National Natural Science Foundation of China 82403511Natural Science Foundation of Zhejiang Province LQ24H160005Natural Science Foundation of Zhejiang Province, Exploration Project/Exploration Public welfare/Medical health LTGY24H160020
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy associated with single-nucleotide variants in VHL, PBRM1, and SETD2. However, the role of structural variation (SV)-which have broader genomic impacts-and 3D genome architecture in ccRCC remains inadequately understood. Here, we reported a comprehensive molecular characterization. Through multi-omics analysis, we identify novel SV-associated oncogenic targets and reveal multidimensional 3D genome reorganization during ccRCC progression. We elucidate the dynamic interplay between SV and 3D chromatin architecture, demonstrating how structural rearrangements drive oncogenic dysregulation through 3D genome reorganization. Notably, an unrecognized pathogenic enhancer hijacking event is discovered and experimentally validated, leading to constitutive activation of the proto-oncogene SEMA5B. Furthermore, we developed a machine learning-based prognostic framework using enhancer hijacking signatures. Collectively, this work establishes a valuable resource for ccRCC research by elucidating how SVs and 3D genome reorganization collectively drive oncogenesis, and translates these findings into a clinically applicable prognostic tool.

Identifiers

PMID41495388
PMCPMC12852824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.